Regeneron Pharmaceuticals
Change company
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
IN
IE
US
US
US
US
US
US
US
US
AU
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
BM
US
US
US
US
US
US
US
US
US
US
US
US
US
JP
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
CA
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
Regeneron Pharmaceuticals (REGN) Business News
Track Regeneron Pharmaceuticals in real time with a live news feed covering Regeneron Pharmaceuticals stock news, official press releases, company announcements, and an archive of historical Regeneron Pharmaceuticals news. ...more
-
CalendarDateSuMoTuWeThFrSaSelected FilterNo selection
Regeneron Strikes Deal With Trump Administration To Cut Drug Prices
Regeneron CEO on deal with Trump admin to lower drug prices
Gear Up for Regeneron (REGN) Q1 Earnings: Wall Street Estimates for Key Metrics
Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.
Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free
Regeneron to offer prescriptions at most favored nation prices, Trump says
SNY & REGN's Dupixent Wins FDA Nod for Pediatric Use in Urticaria
FDA Approves First-Ever Gene Therapy to Restore Hearing
FDA approves Regeneron's gene therapy for inherited deafness
Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.
White House to announce drug pricing deal with Regeneron, source says
FDA approves Regeneron's gene therapy for inherited deafness
Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.
White House to announce drug pricing deal with Regeneron, source says
Regeneron (REGN) Earnings Expected to Grow: Should You Buy?
Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial
Regeneron Announces Investor Conference Presentations
Lbp Am Sa Sells 12,873 Shares of Regeneron Pharmaceuticals, Inc. $REGN
Regeneron Boosts Cancer Pipeline Through Telix Collaboration
SNY & REGN's Dupixent Gets EU Approval for Pediatric Use in Urticaria
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Regeneron Strikes Deal With Trump Administration To Cut Drug Prices
12:08 PM | Friday | Apr 24, 2026
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) has reached an agreement with the U.S. government to lower drug prices, expand patient access, and provide a newly approved gene therapy at no cost, aligning with policy priorities outlined by Donald Trump.
Read full article
Regeneron Strikes Deal With Trump Administration To Cut Drug Prices
BenzingaRegeneron Pharmaceuticals Inc. (NASDAQ:REGN) has reached an agreement with the U.S. government to lower drug prices, expand patient access, and provide a newly approved gene therapy at no cost, aligning with policy priorities outlined by Donald Trump.
Read full article
Regeneron CEO on deal with Trump admin to lower drug prices
CNBC TelevisionRegeneron inked a deal with the Trump administration to lower drug prices and avoid planned tariffs. CEO Leonard Schleifer told CNBC's "Squawk Box" on Friday that "we have to support this industry," but "do it in a way that makes our drugs affordable.
Read full article
Gear Up for Regeneron (REGN) Q1 Earnings: Wall Street Estimates for Key Metrics
Zacks Investment ResearchGet a deeper insight into the potential performance of Regeneron (REGN) for the quarter ended March 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Read full article
Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.
GlobeNewsWireRegeneron will provide Otarmeni™ (lunsotogene parvec-cwha) , its recently approved gene therapy for an ultra-rare form of genetic hearing loss, for free in the U.S.
Read full article
Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free
CNBCRegeneron agreed to lower U.S. drug prices for some Americans as part of a deal with President Donald Trump. The biotech company will also offer the first hearing-loss gene therapy for free to eligible U.S.
patients following regulatory approval of the product.
Regeneron to offer prescriptions at most favored nation prices, Trump says
ReutersU.S. President Donald Trump said on Thursday that Regeneron has agreed to offer prescriptions at most favored nation prices.
Read full article
SNY & REGN's Dupixent Wins FDA Nod for Pediatric Use in Urticaria
Zacks Investment ResearchSanofi wins FDA nod to expand Dupixent in kids aged 2-11 years, marking the first biologic for young patients with uncontrolled CSU.
Read full article
FDA Approves First-Ever Gene Therapy to Restore Hearing
WSJRegeneron's drug restored hearing in 11 of 12 children in a rare, inherited condition that causes deafness.
Read full article
FDA approves Regeneron's gene therapy for inherited deafness
ReutersU.S. Food and Drug Administration has approved Regeneron's gene therapy for a rare genetic form of deafness, the company said on Thursday.
Read full article
Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.
GlobeNewsWireApproval in severe-to-profound and profound OTOF -related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of participants achieved or surpassed a hearing level meeting the primary endpoint, and with longer follow-up, 42% achieved normal hearing that included whispers
Read full article
White House to announce drug pricing deal with Regeneron, source says
ReutersThe White House will announce a drug pricing deal with Regeneron Pharmaceuticals on Thursday, according to a source familiar with the matter.
Read full article
FDA approves Regeneron's gene therapy for inherited deafness
ReutersU.S. Food and Drug Administration has approved Regeneron's gene therapy for a rare genetic form of deafness, the company said on Thursday.
Read full article
Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.
GlobeNewsWireApproval in severe-to-profound and profound OTOF -related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of participants achieved or surpassed a hearing level meeting the primary endpoint, and with longer follow-up, 42% achieved normal hearing that included whispers
Read full article
White House to announce drug pricing deal with Regeneron, source says
ReutersThe White House will announce a drug pricing deal with Regeneron Pharmaceuticals on Thursday, according to a source familiar with the matter.
Read full article
Regeneron (REGN) Earnings Expected to Grow: Should You Buy?
Zacks Investment ResearchRegeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read full article
Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial
GlobeNewsWireAs published in The Lancet and presented at AAN, NIMBLE trial met its primary and key secondary endpoints at week 24, demonstrating potential best-in-class efficacy and convenience in gMG
Read full article
Regeneron Announces Investor Conference Presentations
GlobeNewsWireTARRYTOWN, N.Y., April 20, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
Read full article
Lbp Am Sa Sells 12,873 Shares of Regeneron Pharmaceuticals, Inc. $REGN
Defense WorldLbp Am Sa decreased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 68.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,983 shares of the biopharmaceutical company's stock after selling 12,873 shares during the quarter. Lbp
Read full article
Regeneron Boosts Cancer Pipeline Through Telix Collaboration
Zacks Investment ResearchRegeneron teams up with Telix in a 50/50 radiopharma deal, betting on next-gen cancer therapies to expand its oncology pipeline and long-term growth.
Read full article
SNY & REGN's Dupixent Gets EU Approval for Pediatric Use in Urticaria
Zacks Investment ResearchSanofi wins EC nod to expand Dupixent use to children aged 2 to 11 years with CSU, backed by phase III data, marking the first targeted option in the EU.
Read full article
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Zacks Investment ResearchThe Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read full article